Canada

Medicago

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate

Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 14, 2020

Details:

The Phase I clinical trial is a randomized, partially blinded study of 180 normal healthy subjects and will evaluate dosages of 3.75, 7.5 or 15 micrograms of the recombinant CoVLP vaccine candidate alone or with an adjuvant in a prime-boost regimen.

FSD Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Lead Product(s): Palmitoylethanolamide

Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

FSD Pharma announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.

Symvivo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Symvivo to Start Safety Analysis of a COVID-19 Vaccine Candidate

Lead Product(s): bacTRL-Spike

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 10, 2020

Details:

Symvivo disclosed it was recruiting up to 84 participants for an observed-blinded Phase I clinical trial to evaluate the safety, tolerability and immunogenicity of its bacTRL-Spike.

Appili Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

Lead Product(s): ATI-2307

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

The presentation will highlight Appili’s ATI-2307 program, a novel antifungal for resistant infections that the Company acquired from FUJIFILM Toyama Chemical in 2019.

Orion Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Orion Biotechnology Successfully Completes Phase I Clinical Study of 0b-002h Topical Gel for HIV Prevention

Lead Product(s): 0B-002

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel which is being developed for a HIV prevention indication.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Trial of Metablok to Stop Lung and Kidney Inflammation

Lead Product(s): LSALT peptide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2020

Details:

The Phase II trial will be a multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide.

Appili Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Appili Therapeutics Announces Pricing of Equity Offering

Lead Product(s): ATI-2307

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bloom Burton Securities

Deal Size: $10.2 million Upfront Cash: Undisclosed

Deal Type: Financing February 13, 2020

Details:

The net proceeds of the Offering will be used to fund planned research and development activities for the Company’s four product candidates including ATI-2307, ATI-1701, ATI-1503 and ATI-1501.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Medicago

Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate

FSD Pharma

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Symvivo

Symvivo to Start Safety Analysis of a COVID-19 Vaccine Candidate

Appili Therapeutics

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

Orion Biotechnology

Orion Biotechnology Successfully Completes Phase I Clinical Study of 0b-002h Topical Gel for HIV Prevention

Arch Biopartners

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Trial of Metablok to Stop Lung and Kidney Inflammation

Appili Therapeutics

Appili Therapeutics Announces Pricing of Equity Offering